Literature DB >> 24151800

Complexities of CYP2D6 gene analysis and interpretation.

Andrea Gaedigk1.   

Abstract

Cytochrome P450 2D6 (CYP2D6) plays an important role in the metabolism and bioactivation of about 25% of clinically used drugs including many antidepressants, antipsychotics and opioids. CYP2D6 activity is highly variably ranging from no activity in so-called poor metabolizers to ultrarapid metabolism at the other end of the extreme of the activity distribution. A large portion of this variability can be explained by the highly polymorphic nature of the CYP2D6 gene locus for which > 100 variants and subvariants identified to date. Allele frequencies vary markedly between ethnic groups; some have exclusively or predominantly only been observed in certain populations. Pharmacogenetic testing holds the promise of individualizing drug therapy by identifying patients with CYP2D6 diplotypes that puts them at an increased risk of experiencing dose-related adverse events or therapeutic failure. Inferring a patient's CYP2D6 metabolic capacity, or phenotype, however, is a challenging task due to the complexity of the CYP2D6 gene locus. Allelic variation includes SNPs, small insertions and deletions, gene copy number variation and rearrangements with CYP2D7, a highly related non-functional gene. This review provides a summary of the intricacies of CYP2D6 variation and genotype analysis, knowledge that is invaluable for the translation of genotype into clinically useful information.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24151800     DOI: 10.3109/09540261.2013.825581

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  79 in total

1.  Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.

Authors:  T M Dodgen; C De J Labuschagne; A van Schalkwyk; F E Steffens; A Gaedigk; A D Cromarty; M Alessandrini; M S Pepper
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Serotonin syndrome with a combination of aripiprazole and fluoxetine: a case report.

Authors:  Gamze Bostankolu; Yavuz Ayhan; Fusun Cuhadaroglu; Mumin Kazım Yazıcı
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

3.  In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.

Authors:  Daniel L Hertz; Anna C Snavely; Howard L McLeod; Christine M Walko; Joseph G Ibrahim; Steven Anderson; Karen E Weck; Gustav Magrinat; Oludamilola Olajide; Susan Moore; Rachel Raab; Daniel R Carrizosa; Steven Corso; Garry Schwartz; Jeffrey M Peppercorn; James P Evans; David R Jones; Zeruesenay Desta; David A Flockhart; Lisa A Carey; William J Irvin
Journal:  Br J Clin Pharmacol       Date:  2015-08-02       Impact factor: 4.335

4.  The cytochrome P450 2D6*10 genetic polymorphism alters postoperative analgesia.

Authors:  Xiao-Bin Wei; Xi Xiao; Zhou-Xin Han; Dan-Qin Lin; Ping Yu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

5.  [Effects of CYP2D6*10 on plasma trough concentration of metoprolol in patients with coronary artery disease].

Authors:  Qian Zhu; Weihua Lai; Liwen Li; Hanping Li; Shilong Zhong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-03-30

6.  Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection.

Authors:  Wanqiong Qiao; Suparna Martis; Geetu Mendiratta; Lisong Shi; Mariana R Botton; Yao Yang; Andrea Gaedigk; Raymon Vijzelaar; Lisa Edelmann; Ruth Kornreich; Robert J Desnick; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2018-12-06       Impact factor: 2.533

Review 7.  Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing.

Authors:  Yao Yang; Mariana R Botton; Erick R Scott; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2017-05-04       Impact factor: 2.533

Review 8.  The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics.

Authors:  Ute I Schwarz; Markus Gulilat; Richard B Kim
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

9.  Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure.

Authors:  Ádám Kiss; Ádám Menus; Katalin Tóth; Máté Déri; Dávid Sirok; Evelyn Gabri; Ales Belic; Gábor Csukly; István Bitter; Katalin Monostory
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-02       Impact factor: 5.270

Review 10.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.